FDA Drug Safety Initiative Is "Inadequate," JAMA Editorial Says
This article was originally published in The Pink Sheet Daily
Executive Summary
IoM study of drug safety system is "appropriate," but the "initial steps" proposed by FDA are not enough "to restore the trust and confidence necessary" for agency's public health mission. JAMA editors propose independent drug safety agency, with mandatory Phase IV studies.
You may also be interested in...
Sen. Grassley Plans Legislation On Independence Of FDA Drug Safety Office
Finance Committee chair acknowledges he does not have enough votes for such legislation but says he is starting the "process of educating my colleagues" and "intends to continue that until we get this job done." Grassley's requested GAO report on the Office of Drug Safety will take several months.
Sen. Grassley Plans Legislation On Independence Of FDA Drug Safety Office
Finance Committee chair acknowledges he does not have enough votes for such legislation but says he is starting the "process of educating my colleagues" and "intends to continue that until we get this job done." Grassley's requested GAO report on the Office of Drug Safety will take several months.
Lipitor, Zocor and Pravachol Show Equal Rhabdomyolysis Risk – JAMA Article
The top three statins have a roughly equivalent risk of rhabdomyolysis, a study of health plan prescription data published in the Journal of the American Medical Association concludes